Observation time on subsequent injections of subcutaneous daratumumab may be safely removed from institutional policies to reduce chair time.
Monica Tadros, PharmD, BCPS, BCOP
Advertisement
Articles by Monica Tadros, PharmD, BCPS, BCOP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
5